<DOC>
	<DOCNO>NCT01340326</DOCNO>
	<brief_summary>Angiotensin-converting enzyme inhibitor angiotensin-receptor blocker valsartan ameliorate ventricular remodel myocardial infarction ( MI ) . Although amount drug use previous clinical trial , therefore recommend practical guideline maximum clinical dose , clearly demonstrate whether recommend dose efficacious compare low dose commonly use clinical practice . In addition , impact genetic polymorphism neurohormonal system pharmacological effect explore set post-MI remodeling . Therefore , investigator evaluate whether submaximal dose , low major pivotal trial typically use clinical practice , offer similar benefit post-MI ventricular remodeling .</brief_summary>
	<brief_title>The Impact Dose Angiotensin-receptor Blocker Valsartan Genetic Polymorphism Post-MI Ventricular Remodeling</brief_title>
	<detailed_description>A total 1116 patient leave ventricular ( LV ) dysfunction follow first episode acute ST-elevation MI enrol randomize maximal tolerable dose ( 320 mg/day ) usual dose ( 80 mg/day ) valsartan 12 month 2:1 ratio . Echocardiographic analysis quantify post-MI ventricular remodel genotyping blood sample conduct central core laboratory . Clinical assessment laboratory test perform fix time , genetic polymorphism patient test time admission .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Both gender Age &gt; 18 First episode acute STelevation MI An echocardiographic leave ventricular ejection fraction le 50 % Patients provide write informed consent Contraindications use angiotensin receptor blocker ( ARBs ) ( hypersensitivity , pregnancy , bilateral renal artery stenosis ) Urgent need revascularization procedure Severe heart failure ( need intravenous inotropic support ) Persistent ( &gt; 1 hour ) severe hypotension ( systolic blood pressure &lt; 90 mmHg ) Refractory potentially lethal arrhythmia Hemodynamically significant right ventricular infarction Primary valvular disease Congenital heart disease Idiopathic hypertrophic cardiomyopathy Concomitant inflammatory cardiopathy Significant hepatic dysfunction Significant renal dysfunction Anemia ( hemoglobin &lt; 10 mg/mL ) Psychiatric disorder , alcohol durg abuse Any concomitant disease might interfere drug evaluation ( especially life expectancy le 1 year ) Participation pharmacological study within 2 month Refusal inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Post myocardial infarction ventricular remodel</keyword>
	<keyword>valsartan</keyword>
</DOC>